Patents by Inventor Gabriel Martinez

Gabriel Martinez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220024968
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: July 27, 2021
    Publication date: January 27, 2022
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • Publication number: 20220024967
    Abstract: The invention relates to salts of Compound 1, crystalline forms thereof, methods of their preparation, pharmaceutical compositions thereof and methods of their use
    Type: Application
    Filed: January 7, 2021
    Publication date: January 27, 2022
    Inventors: Nelson B. OLIVIER, Kiran REDDY, Gabriel Martinez BOTELLA, Magnus RONN, Paul A. LASKAR
  • Publication number: 20220024930
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
    Type: Application
    Filed: March 26, 2021
    Publication date: January 27, 2022
    Inventors: Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
  • Publication number: 20220002340
    Abstract: Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b, R12, R16, R17, R19, and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
    Type: Application
    Filed: April 28, 2021
    Publication date: January 6, 2022
    Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Francesco G. Salituro, Andrew Griffin, Maria Jesus Blanco-Pillado
  • Publication number: 20210403502
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Application
    Filed: September 13, 2021
    Publication date: December 30, 2021
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Publication number: 20210403476
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
    Type: Application
    Filed: September 27, 2019
    Publication date: December 30, 2021
    Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
  • Publication number: 20210398082
    Abstract: There is provided a method of automatically determining a compatibility quality score for selecting at least one candidate from a plurality of candidates suitable for a job role, using a machine learning model, characterized in that the method comprising: receiving a candidate information via a communication device of at least one candidate, wherein the candidate information comprises at least one of personal information, an information regarding a specific job assignment, or an input associated with a recruitment process, associated with the at least one candidate; and automatically determining, a compatibility quality score for the candidate based on the candidate information and a set of variables, for each of the plurality of candidates for the job role, and wherein the compatibility quality score is determined by applying a hypothesis through at least one mathematical predictor from among a plurality of mathematical predictors.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 23, 2021
    Inventors: Michele Trevisiol, Andrés García-Poveda, Joaquin Perez-Iglesias, José Gabriel Martinez-Martin, Francisco Javier Fortea, Alvaro de Prada Martinez
  • Publication number: 20210380631
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 9, 2021
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • Publication number: 20210355118
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
    Type: Application
    Filed: April 4, 2018
    Publication date: November 18, 2021
    Inventors: Kiran Reddy, Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
  • Publication number: 20210347812
    Abstract: Described herein are neuro-active steroids of the Formula (I): (I) or a pharmaceutically acceptable salt thereof; wherein R1, R2, Ra, G, X, Y, Z, and n are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Application
    Filed: January 8, 2021
    Publication date: November 11, 2021
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, JR., Boyd L. Harrison, Gabriel Martinez Botella
  • Patent number: 11149056
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1b, n, R2A, R2b, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: September 30, 2017
    Date of Patent: October 19, 2021
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • Patent number: 11149054
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: October 19, 2021
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • Patent number: 11149057
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6 and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: October 19, 2021
    Assignee: Sage Therapeutics, Inc.
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Patent number: 11147877
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, and R3 are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use, e.g., for treating a subject suffering from a disease or disorder described herein.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: October 19, 2021
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Francesco G. Salituro, Boyd L. Harrison
  • Patent number: 11124538
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein R1, R2, Ra, G, X, Y, Z, and n are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: September 21, 2021
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert J. Robichaud, Francesco G. Salituro, Boyd L. Harrison, Gabriel Martinez Botella
  • Patent number: 11117924
    Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: September 14, 2021
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison
  • Patent number: 11111266
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: September 7, 2021
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • Patent number: 11104701
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3a, R3b, R4, R5a, R5b, R6a, and R6b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 31, 2021
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro
  • Publication number: 20210261598
    Abstract: Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 26, 2021
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Gabriel Martinez Botella, Boyd L. Harrison, John Gregory Reid
  • Patent number: 11046728
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: June 29, 2021
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro